Norgine, a prominent European specialty pharmaceutical and consumer healthcare company, has announced a significant leadership change with the appointment of Janneke van der Kamp as its new Chief Executive Officer (CEO), effective 1 January 2025. This move comes as part of the company’s strategy to enhance its mission of delivering transformative medicines to patients and consumers.

The appointment of van der Kamp marks a new chapter for Norgine, which has been undergoing a transformation since the investment of Goldman Sachs Alternatives in 2022. The company, with over €500 million in annual revenues, has been focusing on operational excellence to secure its legacy of innovation and expand into new therapeutic areas.

Van der Kamp brings more than two decades of pharmaceutical industry experience to her new role. She joins Norgine from Grünenthal, where she currently serves as Chief Commercial Officer. Her previous experience includes a 19-year tenure at Novartis, where she held various leadership positions, including Head of Pharma Region Europe.

Peter Stein, Chairman of Norgine, expressed confidence in the new appointment, stating: “With Janneke’s appointment, we have attracted the ideal leader for the next phase of Norgine’s exciting growth. Janneke brings to Norgine a deep understanding of the industry, unmatched energy and passion for improving patients’ and consumers’ lives and a commitment to creating value for shareholders, customers and colleagues.”

Janneke van der Kamp has been appointed the new Chief Executive Officer of Norgine, effective 1 January 2025.

Strategic focus on growth and innovation

Van der Kamp’s appointment aligns with Norgine’s ambition to drive its next growth phase. The company plans to focus on advancing existing brands, developing and commercialising pipeline products, and leveraging its platform through business development initiatives.

The incoming CEO expressed her enthusiasm for the role, saying: “What excites me most is the opportunity to drive the next growth phase at Norgine, with our market leading launch and growth Rx brands, the tremendous Movicol consumer health franchise, and our ambitious plans to accelerate licencing and acquisitions of innovative medicines.”

Norgine’s unique position in the market

With a 120-year history, Norgine has established itself as a key player in the pharmaceutical and consumer healthcare sectors across Western Europe, Australia, and New Zealand. The company’s integrated approach, combining strong commercial capabilities with deep medical, regulatory, and clinical expertise, allows it to deliver high-quality medicines to over 25 million patients annually.

The leadership change at Norgine reflects a broader trend in the pharmaceutical industry, where companies are increasingly focusing on speciality medicines and consumer health products. Van der Kamp’s experience in both sectors could prove valuable as Norgine seeks to balance its prescription drug portfolio with its consumer health offerings.